IDEXX Laboratories Hits 10,000 Imaging Milestone, Redefining Veterinary Diagnostics; What Lies Ahead?

IDEXX Laboratories, Inc. reported robust financial results for the second quarter of 2025, underpinned by strong execution, particularly in their Companion Animal Group (CAG) business. The company’s revenue increased 11% as reported and 9% organically. Growth was driven notably by advancements in their CAG Diagnostic Recurring Revenues, which benefited from significant CAG instrument sales and a strong international performance. However, U.S. same-store clinical visits declined by 2.5%, reflecting broader macroeconomic and sector headwinds impacting the business environment.